Sarepta (SRPT) news
Recent news
Sarepta Therapeutics presents new preclinical data demonstrating robust knockdown of pathogenic DMPK RNA in the nucleus with SRP-1003 in DM1 at 2026 oligonucleotide therapeutics society annual meeting
AInvest Wire · 1d agoChina tech stocks fell in premarket trading, with AgriMetis down 17.5%, Sarepta Therapeutics falling 3.3% and MicroAlgo sliding 2.0%.
China tech stocks experienced declines in premarket trading on October 14, 2026, amid broader market uncertainty. AgriMetis was among the most heavily affected, with its shares down 17.5% in early trading. Sarepta Therapeutics also saw a notable drop, falling 3.3%. Meanwhile, MicroAlgo Inc (MLGO)…
AInvest Wire · 1d agoLockheed Martin, Avio to produce solid rocket motors
Lockheed Martin and Avio have announced a partnership to produce solid rocket motors, marking a significant development in the aerospace and defense sector. The collaboration aims to leverage the technical expertise and manufacturing capabilities of both companies to meet growing demand for…
AInvest Wire · 2d agoSarepta Therapeutics, Inc.: RBC cuts target price to $17 from $19
RBC Capital recently adjusted its price target for Sarepta Therapeutics, Inc. (SRPT), reducing it to $17 from $19, while maintaining its "Sector Perform" rating and "Speculative Risk" designation. This move follows a series of analyst actions over the past several months, reflecting ongoing…
AInvest Wire · 7d agoRegenxbio - Agrees not to sue Sarepta or affiliates over existing Elevidys or AAVrh74-based capsids - SEC filing
Regenxbio Inc. has agreed not to pursue legal action against Sarepta Therapeutics or its affiliates regarding the use of existing Elevidys or AAVrh74-based capsids, according to a recent SEC filing [1]. This agreement appears to resolve potential intellectual property disputes related to gene…
AInvest Wire · Sep 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.